Psilocybin Assisted Therapy Market Outlook:
Psilocybin Assisted Therapy Market size was valued at USD 3.1 billion in 2025 and is projected to reach USD 11.8 billion by the end of 2035, rising at a CAGR of 15.8% during the forecast period, i.e., 2026-2035. In 2026, the industry size of psilocybin assisted therapy is estimated at USD 3.6 billion.
The growing incidence of treatment-resistant mental health conditions and increasing recognition of psilocybin’s therapeutic potential in treating disorders such as depression, anxiety, PTSD, and addiction are the pivotal driving factors for this landscape. This can be testified from the WHO article published in June 2022, which states that approximately 1 out of every 8 people, or around 970 million individuals, live with a mental disorder across all nations. Besides, anxiety affects 301 million people and depression impacts 280 million, including children and adolescents, thereby positively influencing market growth.
Furthermore, the rising investment in psychedelic medicine is also a fueling factor for this landscape, wherein the existence of payer pricing is also fostering a favourable business environment. In this regard IMHO in December 2023 found that that the average annual cost for mental health treatment, including both direct i.e., medications, professional fees, lab tests and indirect expenses transportation, food, and loss of income due to time off work, was approximately ₹72,845 (USD 874.14) per person wherein medication expenses formed the largest portion of direct costs underscoring the urgent need for accessible, affordable mental healthcare.
